Proteomics, Genomics & Microarrays


Cell-Free DNA Isolation Kit Launched Through Exclusive Partnership


Beckman Coulter Life Sciences has launched the Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit through an exclusive partnership with Apostle, a liquid biopsy company. As cfDNA workflows move beyond theoretical and into human health applications, Apostle’s industry-leading chemistry paired with Beckman Coulter Life Sciences’ portfolio of genomic reagents and liquid handling platforms enables researchers to meet the growing demands for sequencing of tumour-derived cfDNA.


Surpassing industry standards for yield and purity of cfDNA, Apostle MiniMax is a magnetic nanoparticle-based kit to extract cfDNA from plasma using manual or automated workflows. Due to limited cfDNA concentration, sufficient yield for next-generation sequencing (NGS) or other downstream applications can require higher volumes of plasma. As the volume increases, issues such as recovery efficiency and workflow complexity often arise. Plasma contains a host of contaminants that are problematic at this scale and can reduce assay sensitivity. Apostle MiniMax technology performs reliably across a range of volume inputs, consistently recovering high quantities of cfDNA, while effectively removing contaminants.


“Beckman Coulter Life Sciences is committed to working collaboratively with our customers to find the best technologies to meet their complex needs,” said Steve Wowk, Director of Genomics, Beckman Coulter Life Sciences.


“We have listened to their ongoing challenges in working with cfDNA and sought to find ways to effectively combat those issues. This includes recognising that an innovative product from a startup like Apostle is the best technology to address these needs.”


“Beckman Coulter Life Sciences’ established global presence and commitment to life sciences makes them an ideal collaborator to provide access to our innovative nucleic acid isolation products to customers around the globe,” said David Ge, President and CEO, Apostle Inc.


More information online: ilmt.co/PL/QGoP 48653pr@reply-direct.com


Streamlined ChIP-seq from Small Cell Numbers and Low Chromatin Concentrations


Porvair Sciences announces version 2.0 of its Chromatrap® ChIP-seq kit - developed to perform chromatin immunoprecipitation (ChIP) with unparalleled sensitivity.


This new Chromatrap® ChIP-seq kit enables researchers to efficiently enrich chromatin, detecting binding of low abundant transcription factors and histone modifications from the smallest quantity of starting material (1000 cells or 50ng).


Using proprietary bead-free technology in parallel with high throughput sequencing - Chromatrap® ChIP-seq kit (version 2.0) streamlines your workflow. Requiring less manual handling steps that other ChIP-seq kits, the new Chromatrap® ChIP-seq kit is very easy-to-use, making it perfect for first time ChIP users.


Chromatrap® ChIP-seq kit (version 2.0) allows users to perform up to 24 ChIP assays from cell collection through to immunoprecipitation, including up to 10 chromatin sample preparations. The kit provides all of the major components required for performing ChIP assays to obtain high quality DNA for Next Generation Sequencing library preparation or qPCR experiments.


With the new Chromatrap® ChIP-seq kit a complete ChIP-to-Sequencing protocol can be completed in just five hours. With selective and sensitive enrichment of low chromatin loading and optimised elution buffer chemistry the new version 2.0 of the Chromatrap’s® ChIP-seq kit enables preparation of the highest quality and quantities of immunoprecipitated DNA.


Other notable developments for the Chromatrap® ChIP-seq kit (version 2.0) include high quality chromatin can now be achieved via sonication or enzymatic digestion, improved antibody binding, greater chromatin loading flexibility and the ability to use increased slurry volumes for difficult samples.


More information online: ilmt.co/PL/0Wl9 48882pr@reply-direct.com


Extended CRISPR Screening Service to Primary Human T Cells Announced


Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, has announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery, enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.


CRISPR screens in primary T lymphocytes have proved challenging, owing to complex issues around the introduction of the screening components and Cas9 in particular. Horizon has adapted its established CRISPRko (knockout) platform to address these issues and to deliver a robust screening platform in human T lymphocytes, which will enable complex biological processes, novel targets and more effective drug therapies to be investigated in a therapeutically relevant cell type.


Horizon has added CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The Company’s extension of its CRISPRko Screening Service strengthens its existing immuno-oncology platform and reinforces its commitment to supporting researchers working in this rapidly growing field of research.


Terry Pizzie, Chief Executive Officer, Horizon Discovery Group, commented: “The successful demonstration of primary human T cells in Horizon’s CRISPR screening platforms is a breakthrough format for our clients working in the immuno-oncology space; enabling them to find gene targets and potential therapeutic avenues in an immediately biologically relevant setting rather than having to work through surrogate cell lines. We expect that this approach will allow our customers to save considerable time and resources in downstream validation, helping them to get therapeutics to the clinic faster.”


48145pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60